| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10.63M | 5.2M | 429K | 250K | 0 | 0 | 11M |
| Revenue Growth % | - | -0.51% | -0.92% | -0.42% | -1% | - | - |
| Cost of Goods Sold | 26.3M | 25.92M | 19.93M | 0 | 1.2M | 1.22M | 925K |
| COGS % of Revenue | 2.48% | 4.98% | 46.46% | - | - | - | 0.08% |
| Gross Profit | -15.68M | -20.72M | -19.5M | 250K | -1.2M | -1.22M | 10.07M |
| Gross Margin % | -1.48% | -3.98% | -45.46% | 1% | - | - | 0.92% |
| Gross Profit Growth % | - | -0.32% | 0.06% | 1.01% | -5.8% | -0.02% | 9.25% |
| Operating Expenses | 38.86M | 7.55M | 10.6M | 96.69M | 106.94M | 128.47M | 84.02M |
| OpEx % of Revenue | 3.66% | 1.45% | 24.7% | 386.76% | - | - | 7.64% |
| Selling, General & Admin | 12.56M | 7.55M | 10.6M | 38.42M | 28.79M | 25.96M | 21.85M |
| SG&A % of Revenue | 1.18% | 1.45% | 24.7% | 153.66% | - | - | 1.99% |
| Research & Development | 26.3M | 25.92M | 19.93M | 58.27M | 79.35M | 103.73M | 63.09M |
| R&D % of Revenue | 2.48% | 4.98% | 46.46% | 233.1% | - | - | 5.74% |
| Other Operating Expenses | -5K | -25.92M | -19.93M | 0 | -1.2M | -1.22M | -925K |
| Operating Income | -28.23M | -28.27M | -30.1M | -96.44M | -108.14M | -129.69M | -73.94M |
| Operating Margin % | -2.66% | -5.44% | -70.16% | -385.76% | - | - | -6.72% |
| Operating Income Growth % | - | -0% | -0.06% | -2.2% | -0.12% | -0.2% | 0.43% |
| EBITDA | -27.44M | -27.41M | -29.09M | -95.11M | -106.94M | -128.47M | -73.02M |
| EBITDA Margin % | -2.58% | -5.27% | -67.81% | -380.44% | - | - | -6.64% |
| EBITDA Growth % | - | 0% | -0.06% | -2.27% | -0.12% | -0.2% | 0.43% |
| D&A (Non-Cash Add-back) | 794K | 860K | 1.01M | 1.33M | 1.2M | 1.22M | 925K |
| EBIT | -28.03M | -28.27M | -34.46M | -95.4M | -106.48M | -123.46M | -73.94M |
| Net Interest Income | -740K | -1.5M | -1.29M | 347K | 1.65M | 6.31M | 3.37M |
| Interest Income | 209K | 128K | 100K | 350K | 1.65M | 6.31M | 3.37M |
| Interest Expense | 949K | 1.63M | 1.39M | 3K | 0 | 0 | 0 |
| Other Income/Expense | -745K | -1.59M | -5.75M | 1.04M | 1.66M | 6.22M | 4.17M |
| Pretax Income | -28.98M | -29.86M | -35.85M | -95.4M | -106.48M | -123.46M | -69.78M |
| Pretax Margin % | -2.73% | -5.74% | -83.57% | -381.61% | - | - | -6.34% |
| Income Tax | 204K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 0.99% | 1% | 1% |
| Net Income | -28.98M | -29.79M | -35.85M | -95.4M | -105.28M | -123.46M | -69.78M |
| Net Margin % | -2.73% | -5.73% | -83.57% | -381.61% | - | - | -6.34% |
| Net Income Growth % | - | -0.03% | -0.2% | -1.66% | -0.1% | -0.17% | 0.43% |
| Net Income (Continuing) | -28.98M | -29.86M | -35.85M | -95.4M | -106.48M | -123.46M | -69.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 19K | -47K | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.34 | -0.93 | -1.06 | -2.76 | -2.74 | -2.58 | -1.44 |
| EPS Growth % | - | 0.31% | -0.14% | -1.6% | 0.01% | 0.06% | 0.44% |
| EPS (Basic) | -1.34 | -0.93 | -1.06 | -2.76 | -2.74 | -2.58 | -1.44 |
| Diluted Shares Outstanding | 21.59M | 33.66M | 33.66M | 34.56M | 38.93M | 47.78M | 48.57M |
| Basic Shares Outstanding | 21.59M | 33.66M | 33.66M | 34.56M | 38.93M | 47.78M | 48.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.66M | 4.51M | 240.68M | 247.29M | 220.43M | 116.41M | 51.23M |
| Cash & Short-Term Investments | 10.86M | 3.7M | 238.6M | 244.98M | 215.51M | 111.47M | 49.05M |
| Cash Only | 10.86M | 3.7M | 238.6M | 244.98M | 215.51M | 111.47M | 49.05M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 281K | 214K | 72K | 1.81M | 539K | 320K | 447K |
| Total Non-Current Assets | 3.98M | 4.83M | 4.26M | 7.13M | 5.3M | 3.25M | 1.19M |
| Property, Plant & Equipment | 3.88M | 4.67M | 4.1M | 6.98M | 5.15M | 3.1M | 1.19M |
| Fixed Asset Turnover | 2.74x | 1.11x | 0.10x | 0.04x | - | - | 9.24x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 97K | 154K | 154K | 154K | 154K | 154K | 0 |
| Total Assets | 16.64M | 9.34M | 244.94M | 254.42M | 225.74M | 119.66M | 52.42M |
| Asset Turnover | 0.64x | 0.56x | 0.00x | 0.00x | - | - | 0.21x |
| Asset Growth % | - | -0.44% | 25.24% | 0.04% | -0.11% | -0.47% | -0.56% |
| Total Current Liabilities | 9.2M | 26.72M | 32.26M | 19.81M | 23.13M | 28.34M | 14.54M |
| Accounts Payable | 1.96M | 5.14M | 2.46M | 1.18M | 4.23M | 3.82M | 1.9M |
| Days Payables Outstanding | 27.21 | 72.37 | 44.97 | - | 1.29K | 1.14K | 750.52 |
| Short-Term Debt | 0 | 9.71M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 169K | 1000K | 1000K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.2M | 8.16M | 3.19M | 0 | 13.93M | 19.11M | 11.8M |
| Current Ratio | 1.38x | 0.17x | 7.46x | 12.48x | 9.53x | 4.11x | 3.52x |
| Quick Ratio | 1.38x | 0.17x | 7.46x | 12.48x | 9.53x | 4.11x | 3.52x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 35.89M | 38.63M | 2.7M | 23.79M | 22.27M | 20.64M | 23.62M |
| Long-Term Debt | 15M | 8.41M | 682K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | -4.59M | 0 | 0 | 3.98M | 2.46M | 836K | 0 |
| Deferred Tax Liabilities | 4.59M | 2.81M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 15.99M | 8.59M | 2.02M | 19.81M | 19.81M | 19.81M | 23.62M |
| Total Liabilities | 45.08M | 65.35M | 34.96M | 43.6M | 45.4M | 48.99M | 38.16M |
| Total Debt | 15M | 18.12M | 682K | 5.37M | 3.98M | 2.46M | 836K |
| Net Debt | 4.14M | 14.42M | -237.92M | -239.61M | -211.53M | -109.01M | -48.21M |
| Debt / Equity | - | - | 0.00x | 0.03x | 0.02x | 0.03x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -29.75x | -17.34x | -21.67x | -32146.67x | - | - | - |
| Total Equity | -28.45M | -56.01M | 209.97M | 210.82M | 180.34M | 70.67M | 14.27M |
| Equity Growth % | - | -0.97% | 4.75% | 0% | -0.14% | -0.61% | -0.8% |
| Book Value per Share | -1.32 | -1.66 | 6.24 | 6.10 | 4.63 | 1.48 | 0.29 |
| Total Shareholders' Equity | -28.46M | -55.96M | 209.97M | 210.82M | 180.34M | 70.67M | 14.27M |
| Common Stock | 750K | 750K | 3K | 4K | 5K | 5K | 6K |
| Retained Earnings | -118.56M | -148.35M | -90.92M | -186.32M | -292.8M | -416.26M | -486.04M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.38M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 19K | -47K | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -35.32M | -9.64M | -36.33M | -62.21M | -90.42M | -104.02M | -71.94M |
| Operating CF Margin % | -3.32% | -1.85% | -84.69% | -248.86% | - | - | -6.54% |
| Operating CF Growth % | - | 0.73% | -2.77% | -0.71% | -0.45% | -0.15% | 0.31% |
| Net Income | -28.98M | -29.86M | -35.85M | -95.4M | -106.48M | -123.46M | -69.78M |
| Depreciation & Amortization | 794K | 860K | 1.01M | 1.33M | 1.2M | 1.22M | 925K |
| Stock-Based Compensation | 2.64K | -6.4K | 3.02M | 25.12M | 14.56M | 13.54M | 8.92M |
| Deferred Taxes | 0 | 6.4K | 4.46M | -686K | 0 | 0 | 0 |
| Other Non-Cash Items | 2.57M | -5.75M | -6.48M | 3K | 13K | 2K | -807K |
| Working Capital Changes | -9.7M | 25.1M | -2.5M | 7.42M | 287K | 4.68M | -11.2M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 446K | 3.13M | -1.66M | 7.99M | 3.41M | 5.28M | -13.46M |
| Cash from Investing | -988K | -1.51M | -590K | -924K | -265K | -98K | 0 |
| Capital Expenditures | -988K | -1.51M | -590K | -924K | -268K | -98K | 0 |
| CapEx % of Revenue | 0.09% | 0.29% | 1.38% | 3.7% | - | - | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 5K | 19K | 0 | 3K | 0 | 0 |
| Cash from Financing | 5.02M | 4M | 271.82M | 69.51M | 61.21M | 77K | 9.51M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 19K | -5K | -19K | -1.91M | -469K | -259K | 296K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -36.3M | -11.15M | -36.92M | -63.14M | -90.69M | -104.11M | -71.94M |
| FCF Margin % | -3.42% | -2.15% | -86.07% | -252.55% | - | - | -6.54% |
| FCF Growth % | - | 0.69% | -2.31% | -0.71% | -0.44% | -0.15% | 0.31% |
| FCF per Share | -1.68 | -0.33 | -1.10 | -1.83 | -2.33 | -2.18 | -1.48 |
| FCF Conversion (FCF/Net Income) | 1.22x | 0.32x | 1.01x | 0.65x | 0.86x | 0.84x | 1.03x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 67K | 6K | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -46.57% | -45.34% | -53.83% | -98.37% | -164.3% |
| Gross Margin | -147.53% | -398.44% | -4546.39% | 100% | - | - | 91.59% |
| Net Margin | -272.69% | -572.96% | -8357.34% | -38160.8% | - | - | -634.33% |
| Debt / Equity | - | - | 0.00x | 0.03x | 0.02x | 0.03x | 0.06x |
| Interest Coverage | -29.75x | -17.34x | -21.67x | -32146.67x | - | - | - |
| FCF Conversion | 1.22x | 0.32x | 1.01x | 0.65x | 0.86x | 0.84x | 1.03x |
| Revenue Growth | - | -51.07% | -91.75% | -41.72% | -100% | - | - |
BioAtla, Inc. (BCAB) reported $11.0M in revenue for fiscal year 2024. This represents a 4% increase from $10.6M in 2018.
BioAtla, Inc. (BCAB) grew revenue by 0.0% over the past year. Growth has been modest.
BioAtla, Inc. (BCAB) reported a net loss of $64.7M for fiscal year 2024.
BioAtla, Inc. (BCAB) has a return on equity (ROE) of -164.3%. Negative ROE indicates the company is unprofitable.
BioAtla, Inc. (BCAB) had negative free cash flow of $43.0M in fiscal year 2024, likely due to heavy capital investments.